Trial Profile
IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Mar 2018
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Agammaglobulinaemia; Common variable immunodeficiency; Immunodeficiency disorders; Wiskott-Aldrich syndrome
- Focus Adverse reactions
- Sponsors Grifols
- 18 Sep 2014 New trial record